NEW ORLEANS, Sept. 08, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr. Reddy’s Laboratories Ltd. (NYSE:RDY), if they purchased the Company’s securities between June 17, 2015 and August 10, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Get Help
Dr. Reddy’s investors should visit us at https://www.claimsfiler.com/cases/view-dr-reddys-laboratories-ltd-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Dr. Reddy’s and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had failed to implement an effective corporate quality control system including but not limited to its manufacturing plants and (ii) as a result of the foregoing, Dr. Reddy’s financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Washington Post Publisher Will Lewis Steps Down After Layoffs
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Anta Sports Expands Global Footprint With Strategic Puma Stake
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



